BCT-100 is cytotoxic against primary blasts from patients. (A) AML blasts from 20 newly diagnosed patients were cultured with BCT-100 (0-4000 ng/mL) for 72 hours. The percentage of viable blasts relative to untreated was determined by flow cytometry. BCT-100 leads to a dose-dependent decrease in AML blast viability. (B) IC₅₀ values for the activity of BCT-100 against AML patient blasts are shown. (C) AML blasts from patients were cultured with 600 ng/mL BCT-100 (OBD) alone, 500 ng/mL cytarabine, or both for 72 hours. The percentage of viable cells relative to control after 72 hours was measured by flow cytometry. BCT-100 cytotoxicity is synergistic in combination with cytarabine (BCT vs combination, P = .0054; cytarabine vs combination, P = .0059; 2-way ANOVA: F_(1,57) = 6.405, P < .0001). (D) The percentage of viable cells following treatment with 600 ng/mL BCT-100 and 500 ng/mL cytarabine was correlated. Sensitivity to BCT-100 correlates moderately with sensitivity to cytarabine (r = 0.5128, P = .0208).